Reports Q2 revenue $86.19M, consensus $71.41M. “Following a strong first quarter, our team closed out a very successful second quarter that we believe continued to reflect the clinical value our tests provide to clinicians and their patients,” said Derek Maetzold, president and chief executive officer of Castle Biosciences (CSTL). “We saw very solid total year-over-year test volume growth in our core revenue drivers, with both DecisionDx-Melanoma and TissueCypher exceeding our volume expectations for the quarter, driving our top-line performance.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL:
- CSTL Earnings this Week: How Will it Perform?
- Castle Biosciences announces DecisionDx-Melanoma test granted BD designation
- Castle Biosciences’ Strategic Partnership with SciBase: A Low-Risk Growth Opportunity in Atopic Dermatitis Testing
- Castle Biosciences enters collaboration, license agreement with SciBase
- Castle Biosciences management to meet virtually with Lake Street